RaySearch Laboratories Resultados de beneficios anteriores

Todavía estamos procesando el último informe de beneficios de esta empresa

Pasado controles de criterios 4/6

Los beneficios de RaySearch Laboratories han disminuido a una tasa media anual de -19.7%, mientras que en la industria Healthcare Services los beneficios crecieron en un 16.1% anualmente. Los ingresos han ido creciendo a una tasa media de 6.6% al año. La rentabilidad financiera de RaySearch Laboratories es de 11.1%, y sus márgenes netos son de 8%.

Información clave

-19.7%

Tasa de crecimiento de los beneficios

-19.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services	-11.7%
Tasa de crecimiento de los ingresos	6.6%
Rentabilidad financiera	11.1%
Margen neto	8.0%
Próxima actualización de resultados	17 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be

Mar 15

Is RaySearch Laboratories (STO:RAY B) A Risky Investment?

Feb 22

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Nov 04

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Mar 30

What Kind Of Shareholders Hold The Majority In RaySearch Laboratories AB (publ)'s (STO:RAY B) Shares?

Feb 23

RaySearch Laboratories' (STO:RAY B) Shareholders Are Down 41% On Their Shares

Feb 02

RaySearch Laboratories AB (publ)'s (STO:RAY B) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 13

These 4 Measures Indicate That RaySearch Laboratories (STO:RAY B) Is Using Debt Reasonably Well

Dec 26

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero RaySearch Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:RAY B Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	1,022	82	558	238
30 Sep 23	987	64	540	229
30 Jun 23	945	53	529	230
31 Mar 23	866	22	498	232
31 Dec 22	844	24	481	239
30 Sep 22	768	-6	477	243
30 Jun 22	693	-38	455	241
31 Mar 22	688	-35	442	238
31 Dec 21	642	-47	422	233
30 Sep 21	613	-46	390	218
30 Jun 21	596	-50	376	204
31 Mar 21	605	-42	368	194
31 Dec 20	652	-9	398	185
30 Sep 20	726	24	421	183
30 Jun 20	751	43	454	181
31 Mar 20	777	74	472	180
31 Dec 19	742	50	446	175
30 Sep 19	727	64	438	168
30 Jun 19	733	85	405	159
31 Mar 19	684	84	384	152
31 Dec 18	627	79	354	148
30 Sep 18	613	118	313	135
30 Jun 18	574	104	297	124
31 Mar 18	575	103	278	115
31 Dec 17	585	118	268	104
30 Sep 17	571	121	252	102
30 Jun 17	586	151	247	100
31 Mar 17	563	160	233	98
31 Dec 16	531	151	223	93
30 Sep 16	472	109	218	89
30 Jun 16	447	94	203	92
31 Mar 16	405	63	193	96
31 Dec 15	398	70	182	102
30 Sep 15	373	78	158	105
30 Jun 15	344	76	140	100
31 Mar 15	319	79	121	96
31 Dec 14	285	60	109	95
30 Sep 14	268	24	141	96
30 Jun 14	235	-4	138	96
31 Mar 14	211	-20	136	94
31 Dec 13	204	-21	133	91
30 Sep 13	191	-1	97	85
30 Jun 13	192	13	87	81

Ingresos de calidad: RAY B tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (8%) de RAY B son superiores a los del año pasado (2.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de RAY B han disminuido en un 19.7% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de RAY B en el último año (243.1%) supera su media de 5 años (-19.7% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de RAY B en el último año (243.1%) superó al de la industria Healthcare Services 70.3%.

RaySearch Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS misses analyst expectations

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

Recent updates

Investor sentiment improves as stock rises 16%

Full year 2023 earnings: EPS misses analyst expectations

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Consensus EPS estimates increase by 10%

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch Laboratories (STO:RAY B) Will Want To Turn Around Its Return Trends

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

Price target increased by 9.5% to kr115

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold kr40m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Director recently bought kr88k worth of stock

Founder recently sold kr1.1m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released

Now 29% undervalued after recent price drop

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold kr20m worth of stock

First quarter 2022 earnings: Revenues miss analyst expectations

Price target increased to kr105

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Price target decreased to kr85.00

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be

Full year 2021 earnings: EPS and revenues miss analyst expectations

Is RaySearch Laboratories (STO:RAY B) A Risky Investment?

Founder recently sold kr5.6m worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Price target decreased to kr85.00

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released

Price target increased to kr105

Insufficient new directors

RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China

Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System

Raysearch Laboratories Announces the Release of Raystation® 11A

Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

RaySearch Laboratories AB (publ) Announces Royal Brisbane and Women's Hospital Treats First Patients Using the Raystation® Treatment Planning System

New 90-day high: kr94.00

Full year 2020 earnings released: kr0.26 loss per share (vs kr1.47 profit in FY 2019)

Desglose de ingresos y gastos
Beta